Use of Synthetic Nanoparticles for the Amplification and Composition Control of Phagocyte-Generated Extracellular Vesicles

Technology

Extracellular vesicles (EVs), membrane enclosed vesicles released by many cell types, are vital for cellular communication. EVs encapsulate various proteins, DNAs, and RNAs found in a cell’s cytosol for delivery to nearby cells, often containing vital information that induces changes in recipient cells. EVs-derived from phagocytes, certain immune cell types such as macrophages, have vital roles to play in the pathology of many diseases, including cancer. Macrophage-derived EVs have therapeutic potential as exogenous drug delivery carriers, or as mediators for in situ direction of cell-to-cell cues. However, their inherent functional variability creates the need for a method to readily generate these vesicles and control their composition. UD inventors have developed a method that employs a synthetic hydrogel nanoparticle (NPs) chemistry to drive extracellular vesicle (EV) secretion from phagocytes, significantly amplifying EV yield without altering the phenotype of the parent cells. This amplification is concentration-dependent, with increased NP delivery enhancing lysosomal activity and redirects the endosomal pathway to boost EV secretion. Excitingly, material can be incorporated into these macrophage-derived EVs. Precise loading of cargo into EVs during their production is achievable, including cargo delivered within the NP platform. The platform can be integrated with other drug delivery and/or nucleic acid delivery systems (ie LNPs, polyplexes, liposomes etc) to generate cargo-containing Macrophage EVs that target non-phagocytic cell populations. By co-delivery of NPs with other cargo-containing platforms, EV secretion from phagocytic cells can be controlled with exogenously delivered cargo and achieve cell-mediated delivery to specific target cells. Overall, this innovation increases macrophage-derived EV yield, diversifies the cargo loading steps, and offers potential for creating innovative drug delivery strategies, contributing to advancements in both therapeutic and biomanufacturing fields.

Benefits

  • Customizable EVs composition
  • Easy to control and amplify macrophage EVs
  • Tunable in situ drug delivery strategy
  • Easily scalable platform

Applications

  • Extracellular Vesicles Companies
  • Biomanufacturing Companies
  • Pharmaceutical Companies